The purpose of this trial is to learn about a trial medicine called MK-1403. Researchers designed MK-1403 to treat a type of heart and blood vessel disease called atherosclerotic cardiovascular disease (ASCVD).
Before giving a trial medicine to people with a health condition, researchers first do clinical trials in healthy people. This trial will help researchers learn about the safety of MK-1403 and if participants tolerate it. Tolerate means participants receive the trial medicine and they do not need to stop taking it due to health problems. The trial will also measure what happens to MK 1403 in a healthy person's body over time.
Eligibility
Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Is in good health
* Has a body mass index (BMI) ≥ 18 and ≤ 32 kg/m\^2
Exclusion Criteria:
* Has history of cancer (malignancy)
* Has a history of significant multiple and/or severe allergies
Primary outcome measure(s)
Number of Participants Who Experience an Adverse Event (AE) — Up to approximately 4 weeks An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.
Number of Participants Who Discontinue the Study Intervention Due to an AE — Up to approximately 2 weeks An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-inf) of MK-1403 — Predose and at designated timepoints (up to 72 hours postdose) Blood samples will be collected to determine the AUC0-inf of MK-1403 in plasma.
Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-last) of MK-1403 — Predose and at designated timepoints (up to 72 hours postdose) Blood samples will be collected to determine the AUC0-last of MK-1403 in plasma.
Maximum Plasma Concentration (Cmax) of MK-1403 — Predose and at designated timepoints (up to 72 hours postdose) Blood samples will be collected to determine the Cmax of MK-1403 in plasma.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.